2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

801. Gene Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Emerging Technologies, Gene Editing, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Vaccines, Gene Therapy, Immunotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Diseases, Bleeding and Clotting, Hemophilia, Bone Marrow Failure Syndromes, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, B Cell Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

4313 Functional perturbation identifies reversible SUMO-associated chromatin silencing of persistent AAV genomes

Giulia Simini, MD, Vincent Muczynski, PhD2, Parth Patel, PhD3, Jenny McIntosh, PhD4, Malo Journou5, Charlotte Vayssiere6, Pratima Chowdary, MD, FRCPath7, Paul Batty, PhD, MBBS, FRCPath8, Christopher Morton9, Jeremy Crawford, PhD10, Ulrike Reiss, MD11, Andrew Davidoff, MD12, Amit Nathwani, MD13
1 Royal Free Hospital, London, United Kingdom, University College London, London, United Kingdom
2 University College London, London, United Kingdom
3 University College London, London, United Kingdom
4 University College London, London, United Kingdom
5 Nantes Université, Nantes, France
6 University College London, London, United Kingdom
7 Royal Free Hospital, London, United Kingdom, University College London, London, United Kingdom
8 Royal Free Hospital, London, United Kingdom, University College London, London, United Kingdom
9 St Jude Children's Research Hospital, Memphis, Tennessee, United States
10 St Jude Children's Research Hospital, Memphis, Tennessee, United States
11 St Jude Children's Research Hospital, Memphis, Tennessee, United States
12 St Jude Children's Research Hospital, Memphis, Tennessee, United States
13 Royal Free Hospital, London, United Kingdom, University College London, London, United Kingdom

Introduction

Long-term persistence of therapeutic adeno-associated virus (AAV) genomes does not necessarily result in sustained transgene expression. Liver biopsy studies have shown that vector genomes can persist in human hepatocytes despite little or no detectable transcription, suggesting epigenetic silencing. Whether this silenced state is reversible and which pathways maintain long-term transgene expression remain unclear. We combined patient liver biopsies with complementary stable human hepatic cell models to investigate the epigenetic regulation of therapeutic AAV genomes.

Methods

Liver biopsies from patients with haemophilia A or B treated in the GO-8 and AGT4HB studies were analysed by RNAscope for vector DNA and RNA under clinical study protocol NCT04817462. HuH7 cells were transduced with AAV2/8-LP1-hFIXco to generate stable clones with high (CL1) or low (CL2) FIX expression. Additional stable HuH7 lines expressing secreted NanoLuc luciferase (AAV2/8-LP1-secNluc) or GFP (AAV2/8-CMV-GFP) were used to validate findings. Vector-associated chromatin was profiled by CUT&RUN. Transcriptional states were perturbed using arsenic trioxide (ATO), the SUMOylation inhibitor TAK-981 and targeted siRNA knockdown. Regulators of early AAV expression were also assessed by siRNA knockdown before AAV-GFP transduction.

Results

Liver biopsies obtained 2-130 months after AAV gene therapy showed vector DNA in 10-73% of hepatocytes despite limited transgene transcription (<25% of transduced cells), consistent with epigenetic silencing. Stable HuH7 clones reproduced these contrasting states, with H3K9me3 enrichment at the FIX promoter in low-expressing CL2, whereas high-expressing CL1 displayed a permissive chromatin state.

Pharmacological perturbation showed that established expression states were reversible. In high-expressing CL1, ATO reduced FIX protein by 50% [n=3, p=0.0004] and FIX mRNA fivefold [p=0.01], accompanied by a threefold increase in transgene-associated H3K9me3 [p=0.02] , without loss of cell viability. Conversely, in low-expressing CL2, TAK-981 increased FIX protein by 50%  [n=3, p=0.03] and FIX mRNA fourfold [p=0.02], with a fivefold reduction in H3K9me3 [p=0.07]. Comparable dose-dependent responses were observed in stable GFP and secNluc lines: TAK-981 increased GFP mean fluorescence intensity up to 5-fold and secreted NanoLuc activity up to 100-fold, without loss of cell viability.

Functional genetic interrogation with selected siRNAs identified distinct regulators of repressed and active transgene transcriptional states. In low-expressing CL2, knockdown of SETDB1 and RNF4 increased FIX transcription by 12-fold and 8-fold, respectively, supporting roles in maintaining transcriptional repression. In contrast, depletion of CREBBP, NFYB, EP300, PML, SUV39H1 and SMARCA4 reduced FIX expression in high-expressing CL1, demonstrating that sustained expression requires continuous transcriptional and chromatin support. In addition, the same panel of siRNA was tested prior to transduction with AAV2/8-CMV-GFP in Huh-7 naïve cells to establish key regulators at transduction. Notably, PML and NFYB displayed context-dependent functions: depletion before transduction enhanced transgene expression, whereas knockdown in established CL1 reduced FIX expression, indicating distinct roles during vector establishment and long-term maintenance.

Conclusions

AAV transgene silencing in stable hepatic cell models is actively maintained yet reversible. SUMO-associated regulation, RNF4 and SETDB1 emerge as candidate mediators of H3K9me3-associated repression, while different regulatory networks govern initial expression and long-term maintenance. Defining these stage-specific mechanisms may guide the design and screening of next-generation AAV vectors with more durable and consistent therapeutic expression.

Giulia Simini, MD: BioMarin - Research Funding